ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2026
Nephrotoxicity and kidney outcomes in pediatric oncology patients.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chronic Kidney Disease in Children Within Five Years After Ifosfamide Chemotherapy for Childhood Cancer: A Dutch Pediatric Oncology Cohort Study.Cancer medicine · 2026Article
- Ten tips for kidney biopsy in cancer patients.Clinical kidney journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) is a serious complication during pediatric cancer treatment. Nephrotoxic medication may increase the risk of developing AKI, which may necessitate modifications to standard treatment and may also increase the risk of chronic kidney disease (CKD). This study investigates the incidence of AKI, the impact of nephrotoxic medications and the association between AKI and the development of CKD.
methodsIn this retrospective national cohort study, we analyzed 1525 pediatric cancer patients treated at the Princess Máxima Center between 2015 and 2021. AKI was classified using KDIGO criteria based on serum creatinine. The effect of nephrotoxic medications and other risk factors on AKI incidence and progression was assessed by using a cause specific hazard regression model. The cumulative incidence of AKI was estimated with a competing risk model with death as competing event. The effect of risk factors on CKD, defined as an eGFR <90 ml/min/1.73 m² 1 year after cancer treatment, was evaluated with a logistic regression.
resultsWe included 1525 patients, 37% experienced AKI. A competing risk model identified treatment with ifosfamide, amphotericin B, acyclovir, and busulfan as strong, independent risk factors for a first episode of AKI. Older age was also associated with an increased risk of AKI.At 1-year follow-up (n = 1159), 13.6% had CKD (eGFR <90 ml/min/1.73 m²), and 2.8% had an eGFR <60. AKI (occurred during treatment) was the strongest predictor of CKD: a single AKI episode increased the risk 2.6-fold, while more episodes increased it nearly 16-fold. Nephrectomy was also identified as independent risk factors for CKD.
conclusionAcute kidney injury (AKI) is common in children with cancer and is strongly associated with an increased risk of chronic kidney disease (CKD). Awareness is crucial for high-risk patients, particularly those receiving nephrotoxic medications, with a history of multiple AKI episodes or a prior nephrectomy. Comprehensive monitoring strategies should be implemented at diagnosis, during therapy, and during the post-treatment period to enable early detection and timely intervention, ultimately reducing the risk of AKI and its progression to CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.